Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-
nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human …

Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase
signaling pathway that has a fundamental role in many biologic processes including …

Epithelial–mesenchymal transition (EMT) is an important process for cancer metastasis,
drug resistance, and cancer stem cells. Activation of fibroblast growth factor receptor 1 …

Background The clinical activity of fibroblast growth factor receptor (FGFR) inhibitors seems
restricted to cancers harbouring rare FGFR genetic aberrations. In preclinical studies, high …

Developments in breast cancer biology over the last years have permitted deconstructing
the molecular profile of the most relevant breast cancer subtypes. This has led to an …

Fibroblast growth factors (FGFs) regulate a plethora of biological functions, in both the
embryonic and adult stages of development, binding their cognate receptors and thus …

Aberrant activation in fibroblast growth factor signaling has been implicated in the
development of various cancers, including squamous cell lung cancer, squamous cell head …

Purpose: FGFR1 is a promising therapeutic target in multiple types of solid tumors, including
head and neck squamous cell carcinoma (HNSCC). FGFR inhibitors have shown great …

Introduction This phase 1, open-label, multicenter, single-arm, dose-escalation study aimed
to evaluate safety, pharmacokinetics (PK), and pharmacodynamics of erdafitinib (JNJ …